AZNAstraZenecaRunning, no new patients
A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC
HER2-mutant Non-Small Cell Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 72 (final count)
- Started
- Jul 13, 2022
- Main results expected
- Nov 4, 2024
- Fully finished
- Dec 31, 2026
- Results posted
- Dec 4, 2024
What counts as success
The trial's main goal(s), called the “primary outcome.”
ICR-assessed ORR (Objective Response Rate)
Measured over: Tumour assessments (per RECIST 1.1) every 6 weeks for the first 48 weeks relative to the date of enrolment and then every 9 weeks thereafter. Assessed up to 28 months. (from date of enrolment to final analysis data cut-off)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05246514 · record last updated 2026-08-18 · checked 2026-11-09 15:47 UTC